Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report

Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report

This case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. This report has shown that the [18F] N -(3-Fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane positron emission tomography findings of the patient revealed that the dopamine hyperactivity in the basal ganglia at baseline was normalized after aripiprazole treatment due to its balancing effect as a dopamine partial agonist.